Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib.

Trial Profile

Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms STIM-2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 29 Oct 2014 Planned number of patients changed from 200 to 220, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top